Post-Market Experience With Ocriplasmin Including Chronic Electrophysiologic Changes.

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacology

Background:

• Intravitreal ocriplasmin is a novel pharmacologic agent for vitreomacular traction, including macular holes.
• Recent safety concerns necessitate further investigation into its effects.

Purpose of the Study:

• To evaluate the efficacy and safety of intravitreal ocriplasmin in treating macular holes.
• To assess the impact of ocriplasmin on retinal function using electroretinography (ERG).

Main Methods:

• Retrospective chart review of nine patients treated with intravitreal ocriplasmin.
• Collection of clinical data and electroretinography (ERG) results before and after treatment.

Main Results:

• Two of eight patients (25%) with macular holes achieved successful closure.
• Three patients experienced significant electroretinogram (ERG) depression, with one case lasting up to 15 months.
• The two patients with successful macular hole closure also showed marked ERG depression.

Conclusions:

• Intravitreal ocriplasmin demonstrated a 25% success rate for macular hole closure in this cohort.
• Long-term loss of rod and cone function, evidenced by ERG changes, is a potential adverse effect.
• Further research is warranted to balance the benefits and risks of ocriplasmin treatment.